STOCK TITAN

[Form 4] New York Times Co. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On 07/25/2025, Gilead Sciences (GILD) EVP, Corporate Affairs & General Counsel Deborah H. Telman filed a Form 4 detailing routine equity-award settlements. Two restricted-stock unit (RSU) tranches vested, converting into 8,743 common shares (8,229 + 514) under transaction code “M”. To satisfy withholding taxes, 3,823 shares were automatically disposed of at $116.20 (code “F”). Net of the tax sale, Telman’s direct ownership increased by 4,920 shares to 42,721 shares.

Post-transaction, the executive still holds 51,521 unvested RSUs (29,875 + 21,646) that will vest over three- and four-year schedules. No open-market purchases or discretionary sales occurred; the filing reflects scheduled vesting rather than a valuation-driven trade. While the additional shares retained signal modest long-term alignment, the event is generally viewed as neutral for investors, providing limited insight into Gilead’s operational or financial outlook.

Il 25/07/2025, Deborah H. Telman, EVP Corporate Affairs e General Counsel di Gilead Sciences (GILD), ha presentato un Modulo 4 che dettaglia le normali liquidazioni di premi azionari. Due tranche di unità azionarie vincolate (RSU) sono maturate, convertendosi in 8.743 azioni ordinarie (8.229 + 514) con codice di transazione “M”. Per coprire le imposte di ritenuta, 3.823 azioni sono state automaticamente vendute a 116,20 $ (codice “F”). Al netto della vendita per tasse, la proprietà diretta di Telman è aumentata di 4.920 azioni raggiungendo 42.721 azioni.

Dopo la transazione, l’esecutivo detiene ancora 51.521 RSU non maturate (29.875 + 21.646) che matureranno secondo piani di tre e quattro anni. Non si sono verificati acquisti sul mercato aperto né vendite discrezionali; la segnalazione riflette una maturazione programmata e non una negoziazione basata su valutazioni. Sebbene le azioni aggiuntive mantenute indichino un modesto allineamento a lungo termine, l’evento è generalmente considerato neutrale per gli investitori, offrendo scarsa indicazione sull’andamento operativo o finanziario di Gilead.

El 25/07/2025, Deborah H. Telman, EVP de Asuntos Corporativos y Consejera General de Gilead Sciences (GILD), presentó un Formulario 4 detallando liquidaciones rutinarias de premios en acciones. Dos tramos de unidades restringidas de acciones (RSU) vencieron, convirtiéndose en 8,743 acciones ordinarias (8,229 + 514) bajo el código de transacción “M”. Para cubrir impuestos retenidos, se dispusieron automáticamente 3,823 acciones a $116.20 (código “F”). Tras la venta para impuestos, la propiedad directa de Telman aumentó en 4,920 acciones hasta 42,721 acciones.

Después de la transacción, la ejecutiva aún posee 51,521 RSU no vencidas (29,875 + 21,646) que se liberarán en planes a tres y cuatro años. No hubo compras en mercado abierto ni ventas discrecionales; el informe refleja una liberación programada en lugar de una operación basada en valoración. Aunque las acciones adicionales retenidas señalan un alineamiento modesto a largo plazo, el evento se considera generalmente neutral para los inversores, proporcionando poca información sobre la perspectiva operativa o financiera de Gilead.

2025년 7월 25일, Gilead Sciences(GILD)의 EVP 기업 업무 및 법률 고문 Deborah H. Telman이 일상적인 주식 보상 정산 내용을 담은 Form 4를 제출했습니다. 두 개의 제한 주식 단위(RSU) 트랜치가 만기되어 8,743 보통주(8,229 + 514)로 전환되었으며, 거래 코드 “M”이 적용되었습니다. 원천징수세를 충당하기 위해 3,823주가 자동으로 116.20달러(코드 “F”)에 처분되었습니다. 세금 매각을 제외한 후 Telman의 직접 소유 주식은 4,920주 증가하여 42,721주가 되었습니다.

거래 후에도 임원은 51,521개의 미만기 RSU(29,875 + 21,646)를 보유하고 있으며, 이는 3년 및 4년 일정에 따라 만기될 예정입니다. 공개 시장에서의 매수나 임의 매도는 없었으며, 이번 신고는 평가 기반 거래가 아닌 예정된 만기를 반영합니다. 추가 보유 주식은 장기적인 적절한 정렬을 시사하지만, 이번 사건은 투자자들에게는 일반적으로 중립적으로 평가되며 Gilead의 운영 또는 재무 전망에 대한 제한된 통찰력을 제공합니다.

Le 25/07/2025, Deborah H. Telman, EVP Affaires Corporatives et Conseillère Générale de Gilead Sciences (GILD), a déposé un formulaire 4 détaillant des règlements courants de primes en actions. Deux tranches d’unités d’actions restreintes (RSU) ont acquis leur pleine propriété, se convertissant en 8 743 actions ordinaires (8 229 + 514) sous le code de transaction « M ». Pour couvrir les impôts à la source, 3 823 actions ont été automatiquement cédées à 116,20 $ (code « F »). Nettes de cette vente fiscale, la détention directe de Telman a augmenté de 4 920 actions pour atteindre 42 721 actions.

Après la transaction, la dirigeante détient encore 51 521 RSU non acquises (29 875 + 21 646) qui seront acquises selon des calendriers de trois et quatre ans. Aucune acquisition sur le marché ouvert ni vente discrétionnaire n’a eu lieu ; le dépôt reflète un acquittement programmé plutôt qu’une transaction motivée par une valorisation. Bien que les actions supplémentaires conservées indiquent un alignement modéré à long terme, l’événement est généralement considéré comme neutre pour les investisseurs, offrant peu d’indications sur les perspectives opérationnelles ou financières de Gilead.

Am 25.07.2025 reichte Deborah H. Telman, EVP Corporate Affairs & General Counsel bei Gilead Sciences (GILD), ein Formular 4 ein, das routinemäßige Abwicklungen von Aktienzuteilungen beschreibt. Zwei Tranchen von Restricted Stock Units (RSU) wurden fällig und wandelten sich in 8.743 Stammaktien (8.229 + 514) mit Transaktionscode „M“ um. Zur Begleichung der Quellensteuern wurden 3.823 Aktien automatisch zu 116,20 $ (Code „F“) veräußert. Nach Abzug des Steuerverkaufs erhöhte sich Telmans Direktbesitz um 4.920 Aktien auf 42.721 Aktien.

Nach der Transaktion hält die Führungskraft weiterhin 51.521 unverfallbare RSUs (29.875 + 21.646), die über drei- und vierjährige Zeitpläne verfallen werden. Es gab keine Käufe am offenen Markt oder diskretionäre Verkäufe; die Meldung spiegelt planmäßige Verfalltermine wider und keine wertorientierte Transaktion. Obwohl die zusätzlichen gehaltenen Aktien eine moderate langfristige Ausrichtung signalisieren, wird das Ereignis von Investoren allgemein als neutral eingestuft und liefert nur begrenzte Einblicke in Gileads operative oder finanzielle Aussichten.

Positive
  • Net share increase: Executive retained 4,920 shares after tax withholding, modestly boosting insider ownership.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting; net +4.9k shares held, no signal on fundamentals.

The transactions are mechanical conversions of RSUs granted years earlier. Code “M” denotes settlement, while code “F” covers tax withholding. Because Telman retained over half of the newly issued shares, the filing leans slightly positive on alignment, yet the absence of open-market buying limits interpretive value. The magnitude—≈$570k gross before withholding—is immaterial relative to GILD’s $100 bn market cap. I therefore classify the impact as neutral.

TL;DR: Standard insider equity cadence; governance impact minimal.

Form 4 confirms compliance with Section 16 reporting and illustrates Gilead’s typical four- and three-year RSU vesting schedules. Telman’s decision not to liquidate beyond tax obligations suggests alignment with shareholders, but does not alter board-level governance considerations. No red flags or policy breaches are evident. Consequently, investor relevance is limited.

Il 25/07/2025, Deborah H. Telman, EVP Corporate Affairs e General Counsel di Gilead Sciences (GILD), ha presentato un Modulo 4 che dettaglia le normali liquidazioni di premi azionari. Due tranche di unità azionarie vincolate (RSU) sono maturate, convertendosi in 8.743 azioni ordinarie (8.229 + 514) con codice di transazione “M”. Per coprire le imposte di ritenuta, 3.823 azioni sono state automaticamente vendute a 116,20 $ (codice “F”). Al netto della vendita per tasse, la proprietà diretta di Telman è aumentata di 4.920 azioni raggiungendo 42.721 azioni.

Dopo la transazione, l’esecutivo detiene ancora 51.521 RSU non maturate (29.875 + 21.646) che matureranno secondo piani di tre e quattro anni. Non si sono verificati acquisti sul mercato aperto né vendite discrezionali; la segnalazione riflette una maturazione programmata e non una negoziazione basata su valutazioni. Sebbene le azioni aggiuntive mantenute indichino un modesto allineamento a lungo termine, l’evento è generalmente considerato neutrale per gli investitori, offrendo scarsa indicazione sull’andamento operativo o finanziario di Gilead.

El 25/07/2025, Deborah H. Telman, EVP de Asuntos Corporativos y Consejera General de Gilead Sciences (GILD), presentó un Formulario 4 detallando liquidaciones rutinarias de premios en acciones. Dos tramos de unidades restringidas de acciones (RSU) vencieron, convirtiéndose en 8,743 acciones ordinarias (8,229 + 514) bajo el código de transacción “M”. Para cubrir impuestos retenidos, se dispusieron automáticamente 3,823 acciones a $116.20 (código “F”). Tras la venta para impuestos, la propiedad directa de Telman aumentó en 4,920 acciones hasta 42,721 acciones.

Después de la transacción, la ejecutiva aún posee 51,521 RSU no vencidas (29,875 + 21,646) que se liberarán en planes a tres y cuatro años. No hubo compras en mercado abierto ni ventas discrecionales; el informe refleja una liberación programada en lugar de una operación basada en valoración. Aunque las acciones adicionales retenidas señalan un alineamiento modesto a largo plazo, el evento se considera generalmente neutral para los inversores, proporcionando poca información sobre la perspectiva operativa o financiera de Gilead.

2025년 7월 25일, Gilead Sciences(GILD)의 EVP 기업 업무 및 법률 고문 Deborah H. Telman이 일상적인 주식 보상 정산 내용을 담은 Form 4를 제출했습니다. 두 개의 제한 주식 단위(RSU) 트랜치가 만기되어 8,743 보통주(8,229 + 514)로 전환되었으며, 거래 코드 “M”이 적용되었습니다. 원천징수세를 충당하기 위해 3,823주가 자동으로 116.20달러(코드 “F”)에 처분되었습니다. 세금 매각을 제외한 후 Telman의 직접 소유 주식은 4,920주 증가하여 42,721주가 되었습니다.

거래 후에도 임원은 51,521개의 미만기 RSU(29,875 + 21,646)를 보유하고 있으며, 이는 3년 및 4년 일정에 따라 만기될 예정입니다. 공개 시장에서의 매수나 임의 매도는 없었으며, 이번 신고는 평가 기반 거래가 아닌 예정된 만기를 반영합니다. 추가 보유 주식은 장기적인 적절한 정렬을 시사하지만, 이번 사건은 투자자들에게는 일반적으로 중립적으로 평가되며 Gilead의 운영 또는 재무 전망에 대한 제한된 통찰력을 제공합니다.

Le 25/07/2025, Deborah H. Telman, EVP Affaires Corporatives et Conseillère Générale de Gilead Sciences (GILD), a déposé un formulaire 4 détaillant des règlements courants de primes en actions. Deux tranches d’unités d’actions restreintes (RSU) ont acquis leur pleine propriété, se convertissant en 8 743 actions ordinaires (8 229 + 514) sous le code de transaction « M ». Pour couvrir les impôts à la source, 3 823 actions ont été automatiquement cédées à 116,20 $ (code « F »). Nettes de cette vente fiscale, la détention directe de Telman a augmenté de 4 920 actions pour atteindre 42 721 actions.

Après la transaction, la dirigeante détient encore 51 521 RSU non acquises (29 875 + 21 646) qui seront acquises selon des calendriers de trois et quatre ans. Aucune acquisition sur le marché ouvert ni vente discrétionnaire n’a eu lieu ; le dépôt reflète un acquittement programmé plutôt qu’une transaction motivée par une valorisation. Bien que les actions supplémentaires conservées indiquent un alignement modéré à long terme, l’événement est généralement considéré comme neutre pour les investisseurs, offrant peu d’indications sur les perspectives opérationnelles ou financières de Gilead.

Am 25.07.2025 reichte Deborah H. Telman, EVP Corporate Affairs & General Counsel bei Gilead Sciences (GILD), ein Formular 4 ein, das routinemäßige Abwicklungen von Aktienzuteilungen beschreibt. Zwei Tranchen von Restricted Stock Units (RSU) wurden fällig und wandelten sich in 8.743 Stammaktien (8.229 + 514) mit Transaktionscode „M“ um. Zur Begleichung der Quellensteuern wurden 3.823 Aktien automatisch zu 116,20 $ (Code „F“) veräußert. Nach Abzug des Steuerverkaufs erhöhte sich Telmans Direktbesitz um 4.920 Aktien auf 42.721 Aktien.

Nach der Transaktion hält die Führungskraft weiterhin 51.521 unverfallbare RSUs (29.875 + 21.646), die über drei- und vierjährige Zeitpläne verfallen werden. Es gab keine Käufe am offenen Markt oder diskretionäre Verkäufe; die Meldung spiegelt planmäßige Verfalltermine wider und keine wertorientierte Transaktion. Obwohl die zusätzlichen gehaltenen Aktien eine moderate langfristige Ausrichtung signalisieren, wird das Ereignis von Investoren allgemein als neutral eingestuft und liefert nur begrenzte Einblicke in Gileads operative oder finanzielle Aussichten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
ROGERS JOHN W JR

(Last) (First) (Middle)
THE NEW YORK TIMES COMPANY
620 EIGHTH AVENUE

(Street)
NEW YORK NY 10018

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEW YORK TIMES CO [ NYT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock(1) 07/24/2025 A 106 A $0 51,954 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Restricted Stock Units ("RSUs") acquired in respect of previously reported RSUs awarded under The New York Times Company 2020 Incentive Compensation Plan in connection with, and with a value equal to, cash dividends paid on The New York Times Company's Class A Common Stock ("Dividend Equivalent RSUs"). Dividend Equivalent RSUs granted in respect of vested RSUs are fully vested at grant. Dividend Equivalent RSUs granted in respect of unvested RSUs will vest on the date that such unvested RSUs vest, which is the date of the Company's first annual meeting following the initial grant.
Remarks:
/s/ Michael A. Brown, Attorney-in-fact for John W. Rogers Jr. 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many GILD shares did Deborah H. Telman acquire on 07/25/2025?

She received 8,743 shares upon RSU vesting.

How many shares were sold or withheld for taxes?

3,823 shares were automatically disposed of at $116.20 to cover taxes.

What is Telman’s total direct Gilead shareholding after the transaction?

Her direct ownership rose to 42,721 common shares.

How many unvested RSUs does Telman still hold?

She retains 51,521 unvested RSUs that will vest over the next three to four years.

Did the filing include any open-market purchases or discretionary sales?

No. All activity was scheduled RSU settlement; the only sale was for tax withholding.
New York Times

NYSE:NYT

NYT Rankings

NYT Latest News

NYT Latest SEC Filings

NYT Stock Data

8.39B
159.65M
1.61%
95.73%
4.24%
Publishing
Newspapers: Publishing Or Publishing & Printing
Link
United States
NEW YORK